Signature Oncology is focused on the development of new cancer diagnostic tests based on an innovative technology platform in melanoma that empowers clinician decision making and advances patient care and treatment.

Our technology is based on unique Interferon Gamma (IFNG/IFN) signatures in melanoma which is a large, growing market characterised by high-cost drug therapies, which are often prescribed without careful analysis of patients who are most likely to benefit from the intervention.

Please feel free to get in touch with our team today to learn more.